Company intelligence / Profile preview

Spirocor

Sunnyvale, California, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Spiracur developed the SNaP Wound Care System, an ultraportable negative pressure wound therapy device for chronic and acute wounds. The system received FDA 510(k) clearance and CE Mark approval. Clinical results demonstrated efficacy in wound healing while allowing patient mobility.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

GE Capital Healthcare Financial Services provided financing

Beyond the preview

Go deeper on Spirocor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spirocor.

Explore the full profile